Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans.
The four dengue virus serotypes (DENV-1-DENV-4) have a large impact on global health, causing 50-100 million cases of dengue fever annually. Herein, we describe the first kinetic T cell response to a low-dose DENV-1 vaccination study (10 PFU) in humans. Using flow cytometry, we found that proinflamm...
Main Authors: | Janet C Lindow, Nathan Borochoff-Porte, Anna P Durbin, Stephen S Whitehead, Kelly A Fimlaid, Janice Y Bunn, Beth D Kirkpatrick |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC3398956?pdf=render |
Similar Items
-
Peripheral CD4+ T cell cytokine responses following human challenge and re-challenge with Campylobacter jejuni.
by: Kelly A Fimlaid, et al.
Published: (2014-01-01) -
Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development
by: Anna P. Durbin, et al.
Published: (2011-09-01) -
A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
by: Usha K. Nivarthi, et al.
Published: (2021-02-01) -
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
by: Stephen S Whitehead, et al.
Published: (2017-05-01) -
Small molecule inhibitors of the Candida albicans budded-to-hyphal transition act through multiple signaling pathways.
by: John Midkiff, et al.
Published: (2011-01-01)